tiprankstipranks
Trending News
More News >
Pa Shun International Holdings Limited (HK:0574)
:0574
Hong Kong Market

Pa Shun International Holdings Limited (0574) AI Stock Analysis

Compare
0 Followers

Top Page

HK:0574

Pa Shun International Holdings Limited

(0574)

Select Model
Select Model
Select Model
Neutral 47 (OpenAI - 5.2)
Rating:47Neutral
Price Target:
HK$0.06
▲(24.00% Upside)
Action:ReiteratedDate:02/03/26
The score is held down primarily by very weak financial performance (declining revenue, ongoing losses, negative equity, and negative free cash flow). Technicals are supportive in the short term (price above major moving averages and positive MACD) but are tempered by overbought signals (high RSI and Stochastic). Valuation provides limited support because the negative P/E reflects unprofitability and no dividend yield is available.
Positive Factors
Industry Exposure
Operating in Medical - Pharmaceuticals provides structurally steady end-market demand and regulatory entry barriers that can sustain long-term revenue opportunity versus cyclical sectors, supporting durable product demand and potential margin resilience over multiple years.
Public Listing (HKEX)
Being listed on HKEX gives the company access to established capital markets and regulatory disclosure frameworks, supporting longer-term financing and investor access. This structural market access helps preserve options for equity or debt funding when needed.
Lean Headcount
A small workforce (97 employees) implies lower structural fixed payroll costs and potential operational agility. Over time this can improve scalability and cost control versus larger peers, aiding margin recovery if revenues stabilize or grow.
Negative Factors
Declining Revenue Trend
Material multi-year revenue decline erodes scale, reduces pricing leverage and increases unit costs, making margin recovery harder. Sustained top-line contraction weakens competitive position and limits reinvestment capacity for R&D or commercial expansion.
Negative Shareholders' Equity
Negative shareholders' equity signals accumulated losses and elevated solvency risk, constraining borrowing capacity and restricting strategic flexibility. Over months this limits ability to raise debt or equity on favorable terms and increases restructuring risk.
Consistent Negative Free Cash Flow
Persistent negative free cash flow indicates operations consume cash rather than generate it, forcing reliance on external funding. This undermines sustainable investment in products or commercialization and raises long-term liquidity and survival concerns.

Pa Shun International Holdings Limited (0574) vs. iShares MSCI Hong Kong ETF (EWH)

Pa Shun International Holdings Limited Business Overview & Revenue Model

Company DescriptionPa Shun International Holdings Limited, an investment holding company, engages in the pharmaceutical distribution activities in the People's Republic of China. It operates through three segments: Pharmaceutical Distribution, Self-Operated Retail Pharmacies, and Pharmaceutical Manufacturing. The Pharmaceutical Distribution segment sells pharmaceutical products to wholesalers, franchise retail pharmacy chain stores, and hospitals and other medical institutions in rural areas. The Self-Operated Retail Pharmacies segment engages in the sale of pharmaceutical and healthcare products, cosmetic products, and daily necessities in self-operated retail pharmacies. The Pharmaceutical Manufacturing segment sells pharmaceutical products manufactured by the company. The company was formerly known as Pa Shun Pharmaceutical International Holdings Limited and changed its name to Pa Shun International Holdings Limited in June 2017. The company was incorporated in 2011 and is based in San Po Kong, Hong Kong. Pa Shun International Holdings Limited is a subsidiary of Praise Treasure Limited.
How the Company Makes MoneyPa Shun International Holdings Limited generates revenue through multiple streams, primarily from the sale of its manufactured consumer goods, including electronics and home appliances. The company operates on a business model that involves designing, producing, and distributing these products to various retailers and wholesalers both domestically and internationally. Key revenue streams include direct sales to retailers, bulk orders from distributors, and partnerships with international brands for private label manufacturing. Additionally, the company may benefit from value-added services such as after-sales support and warranty services, enhancing customer loyalty and driving repeat business. Strategic partnerships with suppliers and logistics companies also play a crucial role in optimizing operational efficiency and cost management, further contributing to its profitability.

Pa Shun International Holdings Limited Financial Statement Overview

Summary
Weak fundamentals: revenue has declined materially over time, profitability is negative (net margin, EBIT and EBITDA margins), the balance sheet shows negative shareholders’ equity (elevated solvency risk), and free cash flow is consistently negative—indicating ongoing losses and poor cash generation.
Income Statement
25
Negative
The company has experienced significant revenue decline over the years, with a notable drop from 2019 to 2024. Gross profit margins have been volatile, and the net profit margin has been negative in recent years, indicating ongoing losses. The EBIT and EBITDA margins are also negative, reflecting operational inefficiencies and financial challenges.
Balance Sheet
20
Very Negative
The balance sheet shows a concerning financial position with negative stockholders' equity, indicating potential insolvency risks. The debt-to-equity ratio cannot be calculated due to negative equity, but high total liabilities relative to assets suggest significant leverage. The equity ratio is negative, further highlighting financial instability.
Cash Flow
30
Negative
The company has consistently reported negative free cash flow, indicating cash outflows exceed inflows from operations. The operating cash flow to net income ratio is negative, reflecting poor cash generation relative to net losses. The free cash flow to net income ratio is also negative, underscoring cash flow challenges.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue86.42M86.55M129.43M71.78M85.91M474.83M
Gross Profit13.74M17.06M29.43M13.30M11.06M17.70M
EBITDA99.00K2.89M19.65M-3.26M-11.85M-11.10M
Net Income-59.80M-15.31M2.35M-43.38M-330.40M-419.19M
Balance Sheet
Total Assets161.96M179.65M206.57M136.09M468.59M503.19M
Cash, Cash Equivalents and Short-Term Investments3.56M15.97M16.51M1.90M2.27M5.26M
Total Debt40.42M44.03M165.97M108.71M99.01M102.71M
Total Liabilities310.43M315.68M322.67M251.60M251.59M225.20M
Stockholders Equity-148.47M-136.04M-116.10M-115.52M-58.50M277.98M
Cash Flow
Free Cash Flow5.39M-1.77M-35.00M-2.35M-22.12M-6.59M
Operating Cash Flow5.49M-1.68M-34.93M-2.32M-21.89M-6.51M
Investing Cash Flow-596.00K-88.00K-65.00K2.98M24.97M-2.43M
Financing Cash Flow-5.96M1.23M49.61M-1.02M-6.07M3.17M

Pa Shun International Holdings Limited Technical Analysis

Technical Analysis Sentiment
Negative
Last Price0.05
Price Trends
50DMA
0.05
Positive
100DMA
0.05
Negative
200DMA
0.05
Positive
Market Momentum
MACD
>-0.01
Positive
RSI
40.58
Neutral
STOCH
36.77
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0574, the sentiment is Negative. The current price of 0.05 is below the 20-day moving average (MA) of 0.06, above the 50-day MA of 0.05, and above the 200-day MA of 0.05, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 40.58 is Neutral, neither overbought nor oversold. The STOCH value of 36.77 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:0574.

Pa Shun International Holdings Limited Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
58
Neutral
HK$63.87M362.73-19.93%-2.91%55.41%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
50
Neutral
HK$118.77M-18.49-11.91%-4.50%75.98%
47
Neutral
HK$73.75M-1.08-9.71%-279.92%
47
Neutral
HK$48.29M4.26-2.40%-40.37%-112.64%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
HK:0574
Pa Shun International Holdings Limited
0.05
0.01
28.21%
HK:1889
Sanai Health Industry Group Company Limited
0.40
0.08
23.44%
HK:0911
Qianhai Health Holdings Ltd.
0.29
<0.01
1.79%
HK:0401
Wanjia Group Holdings Ltd.
0.11
0.04
55.88%
HK:6108
New Ray Medicine International Holding Ltd.
0.21
-0.21
-49.29%
HK:8307
Medicskin Holdings Ltd.
0.16
-0.03
-14.36%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Feb 03, 2026